Wall Street brokerages expect that Aurora Cannabis Inc (NYSE:ACB) will announce earnings of ($0.02) per share for the current quarter, according to Zacks. Four analysts have issued estimates for Aurora Cannabis’ earnings, with the highest EPS estimate coming in at $0.00 and the lowest estimate coming in at ($0.04). Aurora Cannabis reported earnings per share of $0.13 during the same quarter last year, which indicates a negative year-over-year growth rate of 115.4%. The company is scheduled to issue its next quarterly earnings report on Tuesday, September 24th.

According to Zacks, analysts expect that Aurora Cannabis will report full-year earnings of ($0.18) per share for the current fiscal year, with EPS estimates ranging from ($0.19) to ($0.16). For the next financial year, analysts expect that the business will report earnings of ($0.03) per share, with EPS estimates ranging from ($0.10) to $0.04. Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aurora Cannabis.

Aurora Cannabis (NYSE:ACB) last announced its quarterly earnings data on Monday, February 11th. The company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.02. The business had revenue of $41.00 million during the quarter. Aurora Cannabis had a negative net margin of 57.54% and a positive return on equity of 3.95%.

A number of brokerages have recently commented on ACB. TheStreet raised shares of Aurora Cannabis from a “d+” rating to a “c” rating in a research report on Thursday, April 4th. Zacks Investment Research lowered shares of Aurora Cannabis from a “hold” rating to a “sell” rating in a research report on Tuesday. GMP Securities reaffirmed a “hold” rating and set a $9.50 price objective on shares of Aurora Cannabis in a research report on Tuesday, February 12th. Desjardins began coverage on shares of Aurora Cannabis in a research report on Thursday, April 25th. They set a “buy” rating and a $9.07 price objective for the company. Finally, ValuEngine raised shares of Aurora Cannabis from a “hold” rating to a “buy” rating in a research report on Tuesday, March 19th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $9.86.

Large investors have recently bought and sold shares of the stock. Moisand Fitzgerald Tamayo LLC bought a new stake in shares of Aurora Cannabis during the first quarter valued at approximately $25,000. Flagship Harbor Advisors LLC bought a new position in Aurora Cannabis during the fourth quarter worth about $26,000. Carroll Financial Associates Inc. bought a new position in shares of Aurora Cannabis in the first quarter valued at approximately $27,000. Financial Management Professionals Inc. boosted its position in shares of Aurora Cannabis by 586.3% in the first quarter. Financial Management Professionals Inc. now owns 3,061 shares of the company’s stock valued at $28,000 after acquiring an additional 2,615 shares during the period. Finally, Advisory Services Network LLC bought a new position in shares of Aurora Cannabis in the fourth quarter valued at approximately $29,000. 8.35% of the stock is owned by hedge funds and other institutional investors.

Shares of ACB traded down $0.15 during trading hours on Wednesday, reaching $8.23. 534,383 shares of the company traded hands, compared to its average volume of 16,205,299. The firm has a market capitalization of $8.13 billion, a P/E ratio of 68.92 and a beta of 2.82. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.50 and a current ratio of 3.31. Aurora Cannabis has a 1-year low of $4.05 and a 1-year high of $12.52.

Aurora Cannabis Company Profile

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

Featured Article: Quiet Period Expirations

Get a free copy of the Zacks research report on Aurora Cannabis (ACB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.